600865 Disclosed is N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1)&bull PEG 400 (polyethylene glycol)&bullKOAc (potassium acetate). Also disclosed are crystalline form and x-ray powder diffraction patterns of Compound 1&bullPEG 400&bullKOAc, pharmaceutical combinations comprising Compound 1&bullPEG 400&bullKOAc, methods of making Compound 1&bullPEG 400&bullKOAc and the use of Compound 1&bullPEG 400&bullKOAc in the manufacture of a medicament. The medicament is useful in the treatment of cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation- fibrinolysis deficiencies, lipid processing deficiencies, lysosomal storage diseases, neurodegenerative diseases, polyglutamine neurological disorders, spongiform encephalopathies, COPD, dry-eye disease, and Sjogren&rsquos disease.